Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/dth.13290|
|Codice identificativo ISI:||WOS:000562497700001|
|Codice identificativo Scopus:||2-s2.0-85081750825|
|Titolo:||Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults|
|Appare nelle tipologie:||1.1 Articolo in rivista|